New drug duo takes on hard-to-treat cancers
NCT ID NCT05307874
First seen Jan 05, 2026 · Last updated May 20, 2026 · Updated 18 times
Summary
This study tested a new combination of two drugs (ICT01 and low-dose interleukin-2) in 56 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to see if the combo is safe and can shrink tumors or slow their growth. The trial had two parts: first finding the best dose, then testing that dose in specific cancer types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
IUCT Oncopole Claudius Regaud
Toulouse, France
-
Institute Gustave Roussy
Paris, France
-
The Institute of Cancer Research
Sutton, United Kingdom
-
University Carl Gustav Carus
Dresden, Germany
-
Universitätsklinikum Wuerzburg
Würzburg, Germany
Conditions
Explore the condition pages connected to this study.